New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?Video Categories: 2018 ASCO Insights and Video Library
Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.
Dr. Michaelis discusses what approaches she takes for PV patients with unmet clinical needs such as recurrent thrombosis or hemorrhage. Supported through funding from Incyte
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss payer adoption of the Breast Cancer IndexSM (BCI) to ensure patient access and cost reimbursement.